Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company involved in the development of oral drug delivery systems announced that it has entered into definitive agreements to develop novel oral COVID-19 vaccines. The new company, Oravax Medical Inc., is based on Oramed’s proprietary POD™ oral delivery technology and Premas Biotech Pvt. Ltd.’s novel vaccine technology.
The oral vaccine candidate is a virus-like particle triple antigen vaccine that targets three structural proteins, which should make it a better candidate for protection across emerging mutations of the coronavirus.
The oral delivery of the vaccine should allow for widescale inoculation and easier distribution of the vaccine without requiring an injection. In preclinical studies, the oral COVID-19 vaccine promoted both systemic immunity through Immunoglobulin G (IgG), the most common antibody in blood and bodily fluids that protects against viral infections, and Immunoglobulin A (IgA). In preclinical studies, the vaccine was found to be effective after a single oral dose administration. Clinical trials are expected to start in Q2 2021.